19th Feb 2019 08:18
LONDON (Alliance News) - Indivior PLC on Tuesday reported positive results from tests of its proposed Sublocade treatment for opioid addiction.
Data from the phase three trial showed Sublocade met its primary and key secondary endpoints in both dosages, which showed "clinically and statistically difference in percentage abstinence from opioid use" based on urine samples and self-reporting.
Sublocade is being tested as a injection at doses of 300/300 milligrams and 300/100 milligrams.
Chief Scientific Officer Christian Heidbreder said: "Findings show Sublocade administered by healthcare providers delivered sustained buprenorphine exposure for the entire monthly period while increasing abstinence rates and controlling craving and withdrawal symptoms for patients in this pivotal trial, compared to placebo.
"This represents an effective option in the treatment of opioid use disorder," he continued.
"We are proud of the potential impact these data represent for patients on their path to recovery from opioid use disorder and our continuing efforts to partner with the treatment community."
Shares were 0.6% lower on Tuesday in early trade at 117.65 pence each.
Last week, Indivior reported a doubling of 2018 profit, as expenses registered a significant fall. However, revenue was hit by a loss of market share for its Suboxone treatment.
Earlier February, a US court rejected Indivior's appeal for its case against Dr Reddy's Laboratories to be reheard. Dr Reddy's has created a generic of Suboxone, which Indivior has said will cause it "major" disruption.
Related Shares:
Indivior